TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/14/2026
Back to search
Official data from USPTO
BAUSCH HEALTH
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
BAUSCH HEALTH
ST13
US500000087884008Class
5, 41, 44
Filing
87884008
Registration
6974682
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
81
Latest update
05/16/2026
Trademark type
Word
Nice classes
5, 41, 44
Filing date
04/19/2018
Registration date
02/07/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/07/2023
Last transaction
05/16/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
03/12/2014
First use in commerce
03/12/2014
Drawing code
4
Owner type
03
Owner location
Rochester, NY, US
Examiner
DELGIZZI, RONALD ERNEST
Law office
L70
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Bausch & Lomb Incorporated
Representatives
Robert J. Gorman Bausch + Lomb
Technical classification
Nice Classes
Class 5Class 41Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
cardiovascular system; pharmaceutical preparations and substances for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonaryhepatologicalrespiratoryneurologicalrespiratoryneurologicalhormonalpsychiatric and immune system related diseases and disorders; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparationsimmunomodulators; anticholinesterase preparation for the preventiontreatment and alleviation of neurological disorders; Vaginally administered metronidazole gel for use in the treatment of vaginal disorders; intravenous preparations for the treatment of hyperammonemia of all origins; Skin patch for delivering nitroglycerin to a medical patient; anticonvulsants; pharmaceutical preparations and substances for the preventiontreatment and alleviation of stress; pharmaceutical preparations and substances for the preventiontreatment and alleviation of diabetes; pharmaceutical preparations and substances for controlling insulin levels; pharmaceutical preparations and substances for the preventiontreatment and alleviation of hypertension; pharmaceutical preparations and substances for the preventiontreatment and alleviation of angina; pharmaceutical preparations and substances for the cessation of smoking; pharmaceutical preparations and substances for the prevention and treatment of sexually transmitted diseases; pharmaceutical preparations and substances for the prevention and treatment of herpes; pharmaceutical preparations and substances for the preventiontreatment and alleviation of sleep disorders; pharmaceutical preparations and substances for the preventiontreatment and alleviation of acute myocardial infarctions; pharmaceutical preparations and substances for the preventiontreatment and alleviation of symptomatic congestive heart failure; pharmaceutical preparations and substances for the preventiontreatment and alleviation of asymptomatic left ventricular dysfunction; pharmaceutical preparations and substancesfibrinolytic or thrombolytic agents; pharmaceutical preparations and substances for the preventiontreatment and alleviation of pain and inflammationanti-inflammatories and pain relief medication; pharmaceutical preparations and substances for the preventiontreatment and alleviation of migraines; Pharmaceutical preparations and substances for the treatment of epilepsyseizures and neurological and psychological diseases and disorders; Medicines and medicinal preparations for human purposesto support treatment of hemorrhoidschronic venous insufficiency and lymphedema; sanitary preparations for medical purposes; pharmaceutical preparations to support treatment of hemorrhoidschronic venous insufficiency and lymphedema; homeopathic pharmaceutics for use in support treatment of hemorrhoidschronic venous insufficiency and lymphedema and vitamin preparationsall in the form of tablets or powder or soft gelatin capsules or hard gelatin capsules; pharmaceutical preparations and substances for the prevention and treatment of disordersdiseasesconditions and ailments of the cardio-vascular system; pharmaceutical preparations and substances for the prevention and treatment of hypertension; Pharmaceutical preparations for the treatment of nauseaemesis; Acetaminophen sold as an analgesic for the relief of pain; Pharmaceutical productslipid and triglyceride reducing agents for use in the treatment of cardiovascular and heart disease; Diuretic preparations; pharmaceutical preparations and substances for the preventiontreatment and alleviation of pain; anti-depressants; pharmaceutical preparations and substances for the preventiontreatment and alleviation of disordersdiseasesconditions and ailments of the cardiovascular system; pharmaceutical preparations and substances for the preventiontreatment and alleviation of Parkinson's disease; pharmaceutical preparations and substances for the preventiontreatment and alleviation of Huntington's disease; pharmaceutical preparations and substances for the preventiontreatment and alleviation of amyotrophic lateral sclerosis; pharmaceutical preparations and substances for the preventiontreatment and alleviation of Alzheimer's disease; pharmaceutical preparations and substances for the preventiontreatment and alleviation of Tourette Syndrome; pharmaceutical preparations and substances for the preventiontreatment and alleviation of epilepsy; pharmaceutical preparations and substances for the preventiontreatment and alleviation of multiple sclerosis; pharmaceutical preparations and substances for the preventiontreatment and alleviation of cardio-pulmonary disordersdiseasesconditionsailments; pharmaceutical preparations and substances for the preventiontreatment and alleviation of disordersdiseasesconditionsailments of the circulatory system; pharmaceutical preparations and substances for the preventiontreatment and alleviation of hypertensionhigh blood pressureheart failure and ventricular dysfunction; pharmaceutical preparations and substances for the preventiontreatment and alleviation of viral and infectious diseases; pharmaceutical preparations and substances for the preventiontreatment and alleviation of central nervous system disordersdiseasesconditions and ailmentscentral nervous system movement disordersocular motility disordersspinal cord diseasesencephalitiscerebral palsyinsomniamood disordersbipolar disorderseizure disorders; pharmaceutical preparations and substancesfibrinolytic or thrombolytic agents; pharmaceutical preparations and substances for the preventiontreatment and alleviation of disordersdiseasesconditions and ailments of the respiratory system; pharmaceutical preparations and substances for the preventiontreatment and alleviation of disordersdiseasesconditions and ailments of the endocrine system; pharmaceutical preparations for the treatment of immunologic diseasesauto immune motility diseasesimmunologic deficiency syndromesauto immune diseasesAcquired Immune Deficiency Syndrome (AIDS)hypersensitivityallergiestumors of the immunological organs; pharmaceutical preparations and substances for the preventiontreatment and alleviation of disordersdiseasesconditions and ailments of the musculoskeletal systembone diseases and bone degenerative conditions; pharmaceutical preparations and substances for the preventiontreatment and alleviation of migraines; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations and substances for the treatment of polycystic ovary syndrome; pharmaceutical preparations and substances for the treatment of infertility; pharmaceutical preparations and substances for the treatment of diabetes; pharmaceutical preparations and substances for the treatment of heart disease; pharmaceutical preparations and substances for the treatment of pain; pharmaceutical preparations and substances for the treatment of cardiovascular disease; pharmaceutical preparations and substances for the treatment of depression and social anxiety; pharmaceutical preparations and substances for the treatment of insomnia; pharmaceutical preparations and substances for the treatment of sleep disorders; pharmaceutical preparations and substances for the treatment of migraine and neurological disorders; Pharmaceutical preparations for the treatment of cancerneurological and dermatological disorders; pharmaceutical preparations for the treatment of myasthenia gravisdepressionmood/anxiety conditionssolar keratoses and cancer; antidepressants; tranquilizers; nasal spray preparations; Pharmaceutical preparations for the treatment of neuromuscular conditions; Pharmaceutical preparationsretinoidsfor the treatment of skin related diseasescancer and precancerous conditionsdisorders related to the modulation of apoptosis; vitamin supplement distributed by prescription only; pharmaceutical preparationsan oral glucose gel for the treatment of low blood sugar; pharmaceutical preparation for the treatment of headaches; pharmaceutical preparations;diazepam rectal gel; Methyltestosterone for use in the treatment of hormone deficiencies; medicated skin lotion for the relief of itch caused by insect biteseczemasunburn and poison ivy; Preparations and substances for the relief of anorectal discomfortinflammationirritation; hemorrhoidal suppositories; Pharmaceutical preparations for the treatment of irritable bowel syndrome; Drugs to treat opioid-induced constipation; Psychotropic preparations; Cough medicine in the nature of saline solutiona spray for nasal dryness due to allergiescold and flu; Dermotherapeutic preparation for use in the treatment of obesity; pharmaceutical preparations for the treatment of neurological disorders and movement disorders; antiobesity agent in the nature of a pharmaceutical preparation; and alleviation of pain; anti-depressants; pharmaceutical preparations and substances for the preventiontreatment and alleviation of anxietydepressiondepressive disorders and mental illness; tranquilizers and sedatives; pharmaceutical preparations and substances for the preventiontreatment and alleviation of disordersdiseasesconditions and ailments
Class 41
Providing on-line publications in the nature of newsletterspamphlets and bulletins in the field of health issues; newslettersarticlesinformational brochures and web-based tools
Class 44
Providing a website featuring information and advice in the field of health issues
Publications
History of USPTO decisions and trademark events.
81 publications found
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
05/14/2026
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
05/14/2026
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
09/10/2025
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
07/25/2025
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
12/06/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
02/07/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
02/07/2023
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
01/06/2023
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
01/05/2023
SUPC
STATEMENT OF USE PROCESSING COMPLETE
01/03/2023
IUAF
USE AMENDMENT FILED
01/01/2023
EISU
TEAS STATEMENT OF USE RECEIVED
01/01/2023
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
12/28/2022
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
12/21/2022
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
12/14/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
10/10/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/10/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
10/10/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
10/10/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
10/10/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
07/12/2022
EX5G
SOU EXTENSION 5 GRANTED
07/11/2022
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
07/11/2022
EXT5
SOU EXTENSION 5 FILED
06/28/2022
EEXT
SOU TEAS EXTENSION RECEIVED
06/28/2022
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
06/23/2022
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
03/09/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
11/09/2021
EX4G
SOU EXTENSION 4 GRANTED
11/07/2021
EXT4
SOU EXTENSION 4 FILED
11/07/2021
EEXT
SOU TEAS EXTENSION RECEIVED
11/07/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/16/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
10/16/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
10/16/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
06/01/2021
EX3G
SOU EXTENSION 3 GRANTED
05/30/2021
EXT3
SOU EXTENSION 3 FILED
05/30/2021
EEXT
SOU TEAS EXTENSION RECEIVED
05/30/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
12/03/2020
EX2G
SOU EXTENSION 2 GRANTED
12/01/2020
EXT2
SOU EXTENSION 2 FILED
12/01/2020
EEXT
SOU TEAS EXTENSION RECEIVED
12/01/2020
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
11/25/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
05/19/2020
EX1G
SOU EXTENSION 1 GRANTED
05/15/2020
EXT1
SOU EXTENSION 1 FILED
05/15/2020
EEXT
SOU TEAS EXTENSION RECEIVED
05/15/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
05/11/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/11/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
05/11/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
05/11/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
05/11/2020
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
12/31/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/05/2019
PUBO
PUBLISHED FOR OPPOSITION
11/05/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/16/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/28/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
09/28/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
09/28/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
09/28/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
09/28/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/07/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/06/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/06/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/08/2019
GNRT
NON-FINAL ACTION E-MAILED
03/08/2019
CNRT
NON-FINAL ACTION WRITTEN
03/08/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/15/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/14/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/14/2019
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
02/14/2019
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
02/14/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/15/2018
GNRT
NON-FINAL ACTION E-MAILED
08/15/2018
CNRT
NON-FINAL ACTION WRITTEN
08/15/2018
DOCK
ASSIGNED TO EXAMINER
08/09/2018
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
07/13/2018
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
07/13/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/27/2018
NWAP
NEW APPLICATION ENTERED
04/23/2018
Continuous trademark protection
Get notified about every new filing that threatens BAUSCH HEALTH or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.